A Randomized, Single-Center, Single-Blind, Placebo controlled, Investigator Initiated Trial to evaluate the efficacy of Probenecid 500 mg twice daily and 1000 mg twice daily for the Treatment of Non-Hospitalized Patients with COVID-19 infection.

Dr Neelam Pandey0 个研究点目标入组 75 人开始时间: 待定最近更新: 2023年1月9日

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 75

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1.Non-hospitalized Patients with RT-PCR confirmed COVID-19 in <= 48 hours prior to randomization.
•2.Patients with WHO Ordinal Scale score 2 and 3.
•3.Patient has presented within 5 days or less of randomization with at least one early onset COVID-19 symptom (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, vomiting or diarrhea).
•4.Men and non-pregnant women, 18 â?? 65 years of age.
•5.Patient has estimated glomerular filtration rate (eGFR) >=30 mL/min using the Cockcroft-Gault formula.
•6.Willing to participate in this study, signed Informed Consent and willing to participate in regular follow-up during the study.
•7.Able to understand and cooperate with study procedures.

排除标准

•1.Subjects hospitalized:
•a.Patients with severe or critical forms of COVID-19 illness or those who are on ventilator support, ECMO, or shock requiring vasopressor support or those with cytokine storm even not in hospital
•b.Patients hospitalized for treatment of severe illnesses
•c.â??Long COVID-19â?? syndrome (defined as a diverse set of symptoms that persist after a minimum of 4 weeks from the onset of a diagnosed COVID-19 infection. Common symptoms include respiratory system disorders, nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain, and anemia).
•2.Females who are pregnant, breast feeding, or planning a pregnancy.
•3.Patients with known blood dyscrasia and uric acid kidney stones
•4.Females of childbearing potential who do not agree to utilize an adequate effective form of contraception.
•5.Males with partners of child-bearing potential unwilling to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence effective from the first administration of any of the IPs throughout the trial.
•6.Men with partners of child-bearing potential unwilling to ensure that their partner uses an effective method of contraception for the same duration for example, hormonal contraception, intrauterine device, diaphragm with spermicidal gel, or sexual abstinence. Men with pregnant or lactating partners unwilling to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure of the fetus or neonate.
•7.Abstinence is only considered to be an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the patients. Periodic abstinence (e.g., calendar, ovulation, sympathothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
•8.History of alcohol, chemical, or drug abuse or dependence as per DSM IV criteria within past 6 months.
•9.Current active malignancy or history of malignancy within the past five years.
•10.Known hypersensitivity history to Investigational Products or any of its component
•11.Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.
•12.Patients with the following conditions:
•a.Immunosuppression
•c.Current neoplasms
•13.Has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma.
•14.Any other clinically significant abnormal medical condition, which in the Investigatorâ??s judgment, would put the patient at increased risk of illness or injury would interfere with study participation or would interfere with the evaluation or quality of the data.
•15.Investigatorâ??s judgment that participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents.
•16.Is taking or is anticipated to re

研究者

发起方

Dr Neelam Pandey

相似试验

进行中（未招募）

1 期

A study to investigate safety, tolerability, and pharmacokinetics of AZD7503 in healthy Japanese participants.nonalcoholic fatty liver disease

JPRN-jRCT2071230075Ageishi Yuji12

尚未招募

1 期

Phase I SCO-240 single dose studyCholelithiasis

JPRN-jRCT2051210027Araki Takahiro76

进行中（未招募）

不适用

A single-centre, single-blind, randomised, placebo-controlled phase IIa study to investigate the effect of AZD1305 given as an iv infusion on left ventricular performance in patients with left ventricular dysfunctioeft ventricular function in patient with left ventricular dysfunction.

EUCTR2008-001254-41-SEAstraZeneca AB

撤回

1 期

A Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AD-6626 in Normal, Healthy VolunteersThis study is for healthy volunteers. The intended use of the investigational product is the treatment of Fanconi AnemiaBlood - Haematological diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders

ACTRN12615000601538Aldea Pharmaceuticals24

招募中

1 期

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of KDF-07002 in Healthy, Adult VolunteersThis trial is to assess safety and tolerability of KDF-07002 in healthy adult males and dose not focus on any particular health condition or problemOther - Research that is not of generic health relevance and not applicable to specific health categories listed above

ACTRN12609000086268ucleus Network, Ltd.54